Evaluating the Impact and Cost-Effectiveness of Typhoid Conjugate Vaccine Schedules Across Diverse Settings: A Multi-Model Comparison

A multi-model comparison commissioned by the WHO demonstrates that while routine typhoid conjugate vaccination at 9 months with a catch-up campaign and booster is generally the most impactful and cost-effective strategy, the optimal schedule ultimately depends on local incidence rates, case-fatality risks, and assumptions about vaccine waning.

The Gist

Imagine typhoid fever as a relentless, invisible thief that steals health and lives, particularly in communities where clean water and sanitation are scarce. For years, health officials have had a powerful new tool to stop this thief: the Typhoid Conjugate Vaccine (TCV). It's like a high-tech security system for the body.

However, there's a catch. Just like a battery in a flashlight, the protection this vaccine provides doesn't last forever. In some places, the "battery" drains quickly; in others, it lasts longer. The big question facing the World Health Organization (WHO) is: How do we use this vaccine most effectively? Should we give it to babies right away? Should we wait until they are older? And do we need to give them a "recharge" (a booster shot) later on?

To answer this, the authors of this paper didn't just guess. They gathered four different teams of expert mathematicians and epidemiologists (think of them as four different weather forecasters) to build computer simulations. Each team used a slightly different map and set of rules to predict how the disease and the vaccine would interact over the next decade.

Here is what they discovered, broken down into simple concepts:

1. The "Weather Forecast" of Disease

The researchers looked at three types of "climates" where typhoid lives:

• Medium Rain: Moderate number of cases.
• Heavy Rain: Many cases.
• Monsoon: A flood of cases.

They also looked at two types of "batteries":

• Long-Lasting Battery: The vaccine protection fades slowly (like in Malawi).
• Short-Lasting Battery: The vaccine protection fades quickly (like in Bangladesh).

2. The Winning Strategies

The four teams ran thousands of simulations to find the best "game plan." Here is what they found:

• In the "Monsoon" Areas (Very High Incidence):
  The thief is everywhere, and the youngest children are the most vulnerable. The best strategy is to vaccinate babies at 9 months old and then give them a booster shot at 5 years old.

  • Analogy: Imagine a house with a broken roof in a hurricane. You need to patch it immediately (9 months) and then reinforce it again before the next storm season (5 years). This strategy was so effective that in these areas, the money saved by preventing illness actually exceeded the cost of the vaccine. It paid for itself!

• In the "Heavy Rain" Areas (High Incidence):
  The strategy depends on how fast the vaccine "battery" drains.

  • If the battery lasts a long time: Vaccinate at 9 months.
  • If the battery drains fast: It's better to wait and vaccinate at 2 or 5 years old.
  • Analogy: If you know your flashlight battery dies in a week, you don't turn it on for a long hike at the start of the trip. You wait until you are halfway there (older age) to turn it on, so it lasts through the most dangerous part of the journey.

• In the "Medium Rain" Areas (Medium Incidence):
  Here, the disease mostly affects older children (school age). The best move is often to wait and vaccinate at 2 or 5 years old.

  • Analogy: If the thief only comes when the kids are playing in the park (school age), there's no point in locking the front door for the baby who stays inside. Wait until the kids go outside, then lock the door.

3. The Cost of Doing Business

The study also looked at the price tag.

• The "Booster" Cost: Giving an extra shot at 5 years costs more upfront.
• The "Savings": However, in places with many cases, preventing the disease saves so much money on hospital bills and lost work that the booster pays for itself within a few years.
• The "Africa vs. Asia" Factor: The study found that in some regions (modeled after parts of Africa), the disease is more deadly and treatment is more expensive. This makes the vaccine an even better deal there compared to regions (modeled after parts of Asia) where the disease is less deadly.

4. The Big Takeaway

The most important lesson is that one size does not fit all.

There is no single "magic bullet" schedule that works everywhere.

• If the disease is raging and the vaccine fades fast, you need babies + boosters.
• If the disease is slower and the vaccine lasts, you can wait and vaccinate older kids.
• If the disease mostly hits school-age kids, wait until they are older to vaccinate.

Why This Matters

This paper is like a giant instruction manual for countries trying to decide how to spend their limited health budgets. It tells them: "Don't just copy what your neighbor is doing. Look at your own 'weather' (how many cases you have), check your 'battery' (how long the vaccine lasts in your area), and choose the strategy that saves the most lives for the least amount of money."

By using these smart, tailored strategies, countries can stop the typhoid thief more effectively, saving lives and money in the long run.

Technical Summary

1. Problem Statement

Typhoid fever, caused by Salmonella enterica serovar Typhi, remains a significant public health burden in low- and middle-income countries (LMICs), causing millions of cases and hundreds of thousands of deaths annually. While the World Health Organization (WHO) recommended the introduction of Typhoid Conjugate Vaccines (TCVs) in 2018, emerging evidence suggests that vaccine-derived immunity may wane over time, particularly in high-transmission settings.

• The Challenge: There is uncertainty regarding the optimal vaccination schedule. Key questions include:
  • At what age should routine vaccination occur (9 months, 2 years, or 5 years)?
  • Is a booster dose necessary to maintain protection?
  • How do varying rates of vaccine waning (slow vs. fast) and local epidemiological factors (incidence, age of peak infection, case-fatality rates) influence the cost-effectiveness of these strategies?
• The Need: Single-model studies often lack robustness. A multi-model comparison is required to account for structural uncertainties and provide reliable guidance for WHO policy updates.

2. Methodology

The study employed a multi-model comparison framework commissioned by the WHO under the MMC-TAS project.

• Models Used: Four independent mathematical models were utilized:
  • Agent-Based Models (ABM): Burnet Institute and Institute for Disease Modeling (IDM). These simulate transmission at the individual level.
  • Compartmental Models: Stanford University and Yale University. These simulate population flows through infection states.
  • Note: All models were age-structured, included a chronic carrier state, and were calibrated to reproduce harmonized incidence data.
• Study Scenarios:
  • Incidence Settings: Medium (10–99/100k), High (100–499/100k), and Very High (>500/100k) cases per 100,000 person-years.
  • Waning Scenarios:
    • Slow-waning: Based on Malawi trial data (protection maintained >70% for ~4.5 years).
    • Fast-waning: Based on Bangladesh trial data (protection drops significantly, e.g., to ~24% for children <2 years old after 3–5 years).
  • Regional Cost/Severity Profiles: "Africa" (higher Case-Fatality Risk [CFR] and treatment costs) and "Asia" (lower CFR and costs).
• Vaccination Strategies Evaluated (10-year horizon):
  1. No vaccination (Baseline).
  2. Routine vaccination at 9 months + catch-up (9mo–15y).
  3. Routine vaccination at 2 years + catch-up (2–15y).
  4. Routine vaccination at 5 years + catch-up (5–15y).
  5. Routine vaccination at 9 months + booster at 5 years + catch-up.
• Economic Analysis:
  • Perspective: Healthcare payer (excluding indirect costs).
  • Metric: Net Monetary Benefit (NMB) calculated across a range of Willingness-to-Pay (WTP) thresholds ($0–$2,500 per DALY averted).
  • Costs: Included procurement ($1.50/dose), delivery, and treatment costs.
  • Sensitivity: Probabilistic one-way sensitivity analyses and threshold analyses were performed to identify key drivers.

3. Key Contributions

• Robust Multi-Model Consensus: This is the first comprehensive multi-model comparison specifically addressing TCV schedules with waning immunity. It demonstrates that while model structures differ, predictions on optimal strategies are largely consistent when accounting for local epidemiology.
• Waning Dynamics Integration: The study explicitly incorporates recent clinical trial data showing heterogeneous waning rates based on age at vaccination and transmission intensity, moving beyond static efficacy assumptions.
• Context-Specific Optimization: The paper provides a decision framework showing that a "one-size-fits-all" schedule is suboptimal; the best strategy depends heavily on the local age distribution of incidence and the speed of immunity waning.
• Booster Justification: It provides quantitative evidence supporting the addition of booster doses in very high-incidence settings, a strategy previously debated due to cost concerns.

4. Key Results

Vaccine Impact

• Overall Reduction: Over a 10-year horizon, the optimal strategy (Routine 9mo + Booster at 5y) reduced typhoid cases by a median of 48–64% across incidence settings.
• Waning Effects:
  • In slow-waning scenarios, routine vaccination at 9 months provided sustained impact.
  • In fast-waning scenarios, routine vaccination at 9 months showed an initial drop in cases followed by a rebound. Adding a booster at 5 years was critical to sustaining protection.
  • In fast-waning settings, delaying routine vaccination to 2 or 5 years sometimes yielded better long-term results than 9 months, as older children retain protection longer.

Cost-Effectiveness

• Medium Incidence: Vaccination is cost-effective only at higher WTP thresholds (>$1,250/DALY) in high-cost/high-CFR settings. In low-cost/low-CFR settings, it is generally not cost-effective below $2,500/DALY.
• High Incidence:
  • Africa (High CFR): Cost-effective at WTP >$100/DALY. Preferred strategy: 9 months (slow waning) or 2 years (fast waning).
  • Asia (Low CFR): Cost-effective at WTP >$700/DALY. Preferred strategy: 2 years.
• Very High Incidence:
  • Vaccination is cost-saving (savings exceed costs) in both regions.
  • The Booster Strategy (9mo + 5y booster) is consistently cost-effective and often the dominant strategy, even at low WTP values.
• Thresholds: TCV introduction becomes cost-effective when typhoid mortality exceeds 1–4 deaths per 1 million person-years. Adding a booster becomes cost-effective when mortality exceeds 8–20 deaths per 1 million person-years.

Sensitivity Analysis

• The most influential parameters driving results were Case-Fatality Risk (CFR), vaccine coverage, and waning rates.
• The age of peak incidence is a critical determinant: if peaks occur in 2–4 year olds (high incidence), early vaccination is preferred; if peaks shift to 5–15 year olds (medium incidence), delaying vaccination to 5 years may be optimal.

5. Significance and Implications

• Policy Guidance: The findings support updated WHO recommendations that move beyond a single schedule. They suggest:
  • Very High Incidence: Implement routine vaccination at 9 months with a booster at 5 years.
  • High/Medium Incidence: Consider delaying routine vaccination to 2 or 5 years if waning is rapid and the peak incidence is in older children, to maximize the duration of protection.
• Resource Allocation: In very high-burden settings, the health savings from vaccination (and the inclusion of a booster) outweigh the costs, making these interventions highly efficient investments.
• Implementation Strategy: The study highlights the importance of local surveillance to determine the age of peak incidence and the rate of waning. If a rebound in cases is observed post-introduction, booster campaigns should be considered.
• Limitations & Future Work: The study notes limitations in data regarding Antimicrobial Resistance (AMR) costs and the duration of chronic carriage. Future analyses should integrate WASH (Water, Sanitation, and Hygiene) interventions and AMR-specific cost data.

Conclusion:
This multi-model analysis confirms that TCVs remain a critical tool for controlling typhoid in LMICs. However, the optimal schedule is highly context-dependent. The inclusion of a booster dose is strongly supported in very high-incidence settings to counteract rapid waning, while in medium-incidence settings, delaying the primary dose may be more efficient. These insights are vital for national immunization programs to maximize health impact within constrained budgets.